Investigating the effect of vitamin D on headache severity in adolescents

Investigating the effect of vitamin D on headache severity in adolescents with migraine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251116068013N1

Enrollment

112

Registered

2026-05-13

Start date

2026-06-05

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine in children and adolescents. Migraine

Interventions

Intervention 1: The intervention group receives 1000 IU of Vitamin D supplement orally per day for 3 months. In addition, routine treatment including Propranolol tablets (20 mg every 12 hours) and Ami

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: Adolescents aged between 10 and 18 years Definitive diagnosis of migraine by a pediatric neurologist based on ICHD-3 criteria Serum vitamin D levels less than 30 ng/ml (deficiency or insufficiency) Willingness to participate and providing informed consent by parents or legal guardians Absence of chronic underlying diseases (cardiac, renal, or hepatic)

Exclusion criteria

Exclusion criteria: Affliction with chronic systemic diseases (including cardiovascular, renal, hepatic diseases, and hyperthyroidism or hypothyroidism) Use of vitamin D supplements in the past three months Consumption of medications affecting vitamin D metabolism (such as specific anticonvulsants or corticosteroids) Presence of morbid obesity (Body Mass Index or BMI > 30 kg/m²) Diagnosis of Diabetes Mellitus Reluctance of the patient or parents to continue participation at any stage of the study Occurrence of severe adverse effects or hypersensitivity to vitamin D supplementation

Design outcomes

Primary

Measure	Time frame
Headache intensity. Timepoint: Before intervention (Baseline), 1, 2, and 3 months after the start of interventio. Method of measurement: Visual analogue scale.;Duration of headache in hours per day. Timepoint: Before intervention and one month after the intervention and two months after intervention and three months after the intervention. Method of measurement: Daily recording with timer.;Number of the patient’s headache attacks per month. Timepoint: Monthly. Method of measurement: Daily recording.;Vitamin D. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement of Vitamin D.	—

Measure

Time frame

Headache intensity. Timepoint: Before intervention (Baseline), 1, 2, and 3 months after the start of interventio. Method of measurement: Visual analogue scale.;Duration of headache in hours per day. Timepoint: Before intervention and one month after the intervention and two months after intervention and three months after the intervention. Method of measurement: Daily recording with timer.;Number of the patient’s headache attacks per month. Timepoint: Monthly. Method of measurement: Daily recording.;Vitamin D. Timepoint: Before and after intervention. Method of measurement: Laboratory measurement of Vitamin D.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Kouhbanani

Birjand University of Medical Sciences

mohammadkbn2@gmail.com+98 992 461 5428

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026